New Non-Opioid Painkiller Shows Promise in Outperforming Traditional Opioids
A groundbreaking non-opioid drug developed at Duke University shows potential to provide powerful pain relief without the addictive side effects associated with traditional opioids. Preclinical studies reveal SBI-810's promising performance in managing acute and chronic pain safely.
Researchers at Duke University have developed an innovative pain relief drug, SBI-810, which could revolutionize pain management by providing effective relief without the risks associated with opioids. Unlike conventional opioids that activate multiple cellular pathways, SBI-810 specifically targets a receptor in the nervous system linked to pain sensation, avoiding the euphoric effects that lead to addiction. In preclinical studies involving mice, SBI-810 demonstrated notable success by alleviating pain from various sources such as surgical incisions, bone fractures, and nerve injuries. Notably, it outperformed some existing painkillers like gabapentin and showed better efficacy than opioids in certain cases, without causing tolerance or sedation.
The drug works by activating the neurotensin receptor 1 through a mechanism called biased agonism, selectively engaging signals that produce pain relief while sidestepping pathways that result in side effects. This targeted approach holds promise for both acute and chronic pain conditions, including postoperative pain and diabetic nerve pain. Researchers reported that SBI-810 effectively reduced signs of discomfort in animal models, such as guarding and facial grimacing, and did not induce common opioid-related issues like tolerance or constipation.
Despite being in early stages of development, Duke scientists are optimistic about advancing SBI-810 into human trials soon, having secured multiple patents for their discovery. The need for safer pain management options is urgent, especially considering that more than 80,000 Americans die annually from opioid overdoses, in addition to the widespread prevalence of chronic pain affecting a large portion of the population. The specificity of SBI-810's action could make it a safer alternative for managing pain in post-surgical recovery, diabetic nerve pain, and other conditions, offering effective relief while minimizing risks of addiction and side effects.
This breakthrough highlights a promising direction in pain medicine—leveraging targeted receptor activation to provide powerful, safe, and non-addictive pain relief options.
source: https://medicalxpress.com/news/2025-05-experimental-painkiller-outsmart-opioids-high.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Insights into Alcohol-Induced Liver Damage: Formation of 'Pseudosynapses' and Inflammation Mechanisms
Recent studies reveal that alcohol damages liver cells, forming 'pseudosynapses' with immune cells to facilitate direct communication, triggering inflammation and liver injury. These findings open new possibilities for early diagnosis and targeted treatments of alcohol-associated liver disease.
Innovative Modified CAR-T Cells Target Common Protein in Multiple Cancers
Researchers have developed a groundbreaking CAR-T cell therapy targeting the Eva1 protein, offering new hope for treating solid tumors with high specificity and safety. Discover how this innovation could revolutionize cancer immunotherapy.
Innovative Treatment Shows Promise for Rare Childhood Mitochondrial Disease
A groundbreaking study at NYU Langone Health introduces an experimental compound that shows promise in treating HPDL deficiency, a rare mitochondrial disease in children, leading to notable neurological recovery.
